Nevro LLC (NVRO) Stock Price
Nevro LLC Price
Over the last 12 years Nevro LLC grew revenue by 29.6% annually, reaching 408.52 M USD. For Nevro LLC, the net margin of -27.8% is down versus -22.9% a few years ago. The consensus 12-month price target for Nevro LLC is 5.97 USD, about 2.2% above where the stock trades today. Of 19 analysts, 0 rate the stock a buy — an overall Hold consensus.
Nevro LLC stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Nevro LLC over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Nevro LLC stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Nevro LLC's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Nevro LLC Price |
|---|
Nevro LLC Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Nevro LLC Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.00 | 69.00 | 228.00 | 326.00 | 387.00 | 390.00 | 362.00 | 386.00 | 406.00 | 425.00 | 408.00 | 407.00 | 424.00 | 446.00 | 478.00 | 503.00 |
| 39.13 | 115.63 | 230.43 | 42.98 | 18.71 | 0.78 | -7.18 | 6.63 | 5.18 | 4.68 | -4.00 | -0.25 | 4.18 | 5.19 | 7.17 | 5.23 |
| 65.63 | 59.42 | 67.11 | 69.63 | 70.54 | 68.72 | 68.78 | 68.91 | 67.98 | 68.24 | 65.93 | 65.93 | 65.93 | 65.93 | 65.93 | 65.93 |
| 21.00 | 41.00 | 153.00 | 227.00 | 273.00 | 268.00 | 249.00 | 266.00 | 276.00 | 290.00 | 269.00 | 268.34 | 279.55 | 294.05 | 315.15 | 331.63 |
| -28.00 | -62.00 | -25.00 | -29.00 | -42.00 | -96.00 | -63.00 | -90.00 | 10.00 | -99.00 | -126.00 | -79.00 | -83.00 | -87.00 | -94.00 | -98.00 |
| -87.50 | -89.86 | -10.96 | -8.90 | -10.85 | -24.62 | -17.40 | -23.32 | 2.46 | -23.29 | -30.88 | -19.41 | -19.58 | -19.51 | -19.67 | -19.48 |
| -30.00 | -67.00 | -31.00 | -36.00 | -49.00 | -103.00 | -83.00 | -131.00 | 3.00 | -92.00 | -113.00 | -78.00 | -66.00 | -73.00 | -59.00 | -47.00 |
| 15.38 | 123.33 | -53.73 | 16.13 | 36.11 | 110.20 | -19.42 | 57.83 | -102.29 | -3,166.67 | 22.83 | -30.97 | -15.38 | 10.61 | -19.18 | -20.34 |
| 14.23 | 28.00 | 28.82 | 29.66 | 30.21 | 31.23 | 34.51 | 34.97 | 35.48 | 36.28 | 37.62 | 37.62 | 37.62 | 37.62 | 37.62 | 37.62 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Nevro LLC generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Nevro LLC retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Nevro LLC's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Nevro LLC has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Nevro LLC's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Nevro LLC stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Nevro LLC Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Nevro LLC business model & stock analysis
Nevro LLC SWOT Analysis
Strengths
Nevro Corp exhibits several strengths that contribute to its success:
- Advanced technology: Nevro Corp utilizes state-of-the-art neurostimulation technology, giving it a competitive edge.
- Strong intellectual property: The company holds numerous patents, safeguarding its technology and providing market exclusivity.
- Established brand: Nevro Corp has developed a reputable brand known for its quality and innovative medical devices.
- Effective marketing strategy: The company effectively promotes its products to healthcare professionals and potential customers.
- Global presence: Nevro Corp has expanded its market reach and operates in multiple countries, boosting its growth potential.
Weaknesses
Despite its strengths, Nevro Corp faces certain weaknesses that could hinder its performance:
- Relatively higher costs: The production and distribution costs of Nevro Corp's advanced devices can be higher compared to competitors.
- Dependency on key markets: The company's success heavily relies on a few key markets, making it vulnerable to fluctuations in those regions.
- Limited product range: Nevro Corp's product portfolio is focused on neurostimulation devices, limiting its diversification opportunities.
- Market competition: The neurostimulation industry is highly competitive, with other established players and new entrants vying for market share.
Opportunities
Nevro Corp has several opportunities to capitalize on in the market:
- Expanding applications: There is potential to further develop and explore new medical applications for neurostimulation technology.
- Emerging markets: Nevro Corp can target and expand into emerging markets where there is increasing demand for advanced medical devices.
- Innovation and R&D: Continued investment in research and development can lead to the introduction of new and improved products.
- Partnerships and collaborations: Collaborating with healthcare institutions and professionals can enhance the adoption of Nevro Corp's technologies.
Threats
Nevro Corp faces various threats that may impact its growth and profitability:
- Regulatory challenges: Evolving regulations and compliance requirements can pose obstacles to product development and market entry.
- Market saturation: The neurostimulation market may become saturated, making it difficult for Nevro Corp to maintain its market share.
- Technological advancements: Rapid technological advancements by competitors can render Nevro Corp's current offerings obsolete.
- Economic factors: Economic downturns or financial instability can negatively influence the purchasing power and demand for medical devices.
Nevro LLC Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Nevro LLC Segments
Nevro LLC Revenue by Segment (1/2)
3 Years
5 Years
10 Years
25 Years
Max
Details
Nevro LLC Revenue by Segment (2/2)
Max
Details
Nevro LLC Revenue by Region
3 Years
5 Years
Max
Details
Nevro LLC Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Nevro LLC historical P/E ratio, EBIT multiple, and P/S ratio
Nevro LLC annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Nevro LLC shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Nevro LLC forecasts and price targets in August 2026
Analyst Price Targets 2026Nevro LLC Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 2/7/2025 | Upgrade | UnderweightNeutral | 51 | |
| 2/7/2025 | Maintained | Hold | 59 | |
| 12/18/2024 | Maintained | Hold | – | |
| 12/11/2024 | Maintained | Equal Weight | 56 | |
| 12/11/2024 | Maintained | Neutral | 48 | |
| 12/9/2024 | Maintained | Hold | 59 | |
| 12/2/2024 | Downgrade | Equal WeightUnderweight | 60 | |
| 11/12/2024 | Maintained | Sector Perform | 52 | |
| 11/12/2024 | Maintained | Underweight | 51 | |
| 11/12/2024 | Maintained | Hold | 59 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Nevro LLC Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/11/2024 | -0.83USD | - | 94.93 MUSD | - | 2024 Q3 |
| 4/24/2024 | -0.76USD | - | 101.15 MUSD | - | 2024 Q1 |
| 2/14/2024 | -0.50USD | - | 111.39 MUSD | - | 2023 Q4 |
| 8/1/2023 | -0.52USD | - | 114.62 MUSD | - | 2023 Q2 |
| 5/2/2023 | -0.59USD | - | 102.50 MUSD | - | 2023 Q1 |
| 2/21/2023 | -0.48USD | - | 114.24 MUSD | - | 2022 Q4 |
| 11/2/2022 | -0.10USD | - | 100.72 MUSD | - | 2022 Q3 |
| 8/3/2022 | -0.83USD | - | 106.08 MUSD | - | 2022 Q2 |
| 5/4/2022 | -1.12USD | - | 87.48 MUSD | - | 2022 Q1 |
| 2/23/2022 | -0.88USD | - | 101.76 MUSD | - | 2021 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Nevro LLC stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Nevro LLC shareholder structure
| % | Name |
|---|---|
0.17688% | |
0.15180% | |
0.09791% | |
0.07235% | |
0.07092% | |
0.06396% |
Nevro LLC Beneficial Ownership Filings (SEC 13D/G)
Nevro LLC Executives and Management Board
9 members · avg. age 55 · 0 % women
Mr. Kevin Thornal (50)
President, Chief Executive Officer, Director · since 2023
11.45 M USD
Management
Mr. Greg Siller (43)
Senior Vice President, Chief Commercial Officer
Mr. Christopher Christoforou (54)
Chief Operating Officer
Mr. Roderick Macleod (57)
Chief Financial Officer, Senior Vice President
Mr. Kashif Rashid (50)
Senior Vice President - Corporate Development, Chief Legal Officer
Dr. David Caraway (67)
Senior Vice President, Chief Medical Officer
Mr. Donald Middlebrook (73)
Senior Vice President - Clinical, Regulatory and Quality
Board of Directors
Mr. Keith Pfeil (45)
Director
Mr. Daniel Scavilla (59)
Director
Frequently asked questions about Nevro LLC
Nevro Corp, a leading medical device company, operates on a unique business model. They specialize in developing and commercializing innovative solutions for the treatment of chronic pain. Nevro Corp's flagship product, the Senza® system, stands as a breakthrough technology in the field of spinal cord stimulation. This system offers patients suffering from chronic pain a non-opioid alternative for managing their condition. By focusing on pioneering therapies and eluding traditional opioid-based pain treatments, Nevro Corp is dedicated to enhancing the quality of life for individuals struggling with chronic pain conditions. With its innovative business approach, Nevro Corp aims to revolutionize pain management solutions in the healthcare industry.
Nevro Corp is primarily active in the medical device industry.
The main competitors of Nevro Corp in the market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, and Stryker Corporation.
Nevro Corp is a medical device company that specializes in developing innovative solutions for the treatment of chronic pain. Founded in 2006, Nevro has been a pioneer in the field of spinal cord stimulation. The company's flagship product, the Senza System, is designed to provide long-lasting pain relief without the side effects of traditional opioids. With a strong focus on research and development, Nevro has continued to expand its product portfolio and establish itself as a leader in the industry. Today, Nevro is trusted by healthcare professionals worldwide for its advanced therapies and commitment to improving patients' quality of life.
Nevro Corp, a leading medical device company, has achieved several significant milestones. Firstly, the company developed the breakthrough Senza® system, a spinal cord stimulation platform that offers superior pain relief for patients suffering from chronic pain. This innovative technology has revolutionized the field of neuromodulation. Furthermore, Nevro Corp successfully obtained FDA approval for the Senza system, allowing them to market it in the United States. The company has expanded its global presence as well, receiving regulatory approvals in various countries worldwide. These achievements have solidified Nevro Corp's position as a pioneering entity in the medical device industry, dedicated to improving the lives of patients worldwide.
Nevro Corp is primarily present in various countries and regions worldwide. The company has a global presence and operates in key markets including the United States, Europe, Australia, and Canada. With its innovative medical technology solutions, Nevro Corp aims to improve the lives of patients suffering from chronic pain across these regions.
Nevro Corp represents a strong commitment to improving the lives of patients suffering from chronic pain. With a focus on innovation and advanced technology, Nevro prioritizes patient-centered solutions. The company's corporate philosophy revolves around providing effective and long-lasting relief to individuals in need. Nevro Corp aims to enhance the quality of life by offering non-opioid, evidence-based therapies that deliver superior results. By combining scientific expertise, cutting-edge research, and a patient-centric approach, Nevro Corp strives to make a meaningful impact in the field of chronic pain management.
Analysts currently set an average price target of 8.87 USD for the Nevro LLC stock (median: 5.97 USD), implying +51.9 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the Nevro LLC stock: 0 recommend buying, 15 holding and 4 selling. For 2026, analysts expect Nevro LLC to generate revenue of 424.42 M USD and earnings per share of -1.76 USD.
Converted at the current exchange rate, the Nevro LLC share trades at 5.06 EUR (5.84 USD).
The Nevro LLC share (NVRO) is listed on 4 stock exchanges, including: NYSE (NVRO), Frankfurt (1N7.F), Düsseldorf (1N7.DU), SIX (Zürich) (1N7.SW).
Nevro Corp is a globally operating, publicly traded company that specializes in the development and marketing of innovative medical products for the treatment of chronic pain. The company's business model is based on the use of groundbreaking technologies to alleviate pain in millions of patients worldwide. The company operates in two business segments: manufacturing and product services, as well as research and development. Product services include the marketing of both implanted and external pain relief devices, including the flagship product Senza®. These devices utilize a novel technology called HF10® to effectively combat pain. Unlike traditional devices that promise pain relief through electrical signals, HF10® uses state-of-the-art high-frequency technology to stimulate the spinal cord, resulting in deeper and more effective pain relief. In addition to the Senza® product line, Nevro also has several micro-catheter solutions in its portfolio. These catheters also use HF10® technology, but in a different way for pain treatment. The company is committed to continuously developing and bringing to market new, innovative pain relief solutions to improve the lives of patients worldwide. Nevro Corp's R&D department focuses on pain research and the development of pain relief technologies. The company collaborates with leading research institutions worldwide and invests sustainably in clinical research to improve the effectiveness of its products and obtain approvals and further market clearances in various countries. Furthermore, Nevro also offers a wide range of services to support hospitals and medical professionals in the provision of pain therapies and treatments. This includes a training program for medical personnel to ensure safe and effective use of the devices, as well as a support team available around the clock to address questions and technical issues. Nevro Corp is committed to creating a comprehensive pain relief experience for patients, healthcare professionals, and stakeholders. The company relies on a combination of innovative technologies, clinical research, and expert services to achieve this goal. In summary, Nevro Corp offers pain solutions based on its groundbreaking HF10® technology. The devices demonstrate high effectiveness in pain relief and are one of the most recommended pain therapies in modern clinics. The company continuously invests in research and development to improve its technology and introduce new products to the market. Nevro Corp supports doctors, medical personnel, and patients with a wide range of services to ensure that all parties have access to safe and effective pain treatment.
The expected revenue of Nevro LLC is 424.42 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Nevro LLC is -66.29 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Nevro LLC is currently -3.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Nevro LLC stock.
The price-to-sales ratio (P/S) of Nevro LLC is currently 0.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Nevro LLC stock.
The Eulerpool Quality Score for Nevro LLC is 2/10.
The ISIN of Nevro LLC is US64157F1030. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Nevro LLC is A12EPL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Nevro LLC is NVRO. The ticker symbol is used to trade Nevro LLC shares on the stock exchange.
Nevro LLC paid dividends every year for the past 0 years.
Nevro LLC is assigned to the 'Health' sector.
The dividends of Nevro LLC are distributed in USD.
Nevro LLC stock
Nevro LLC Peer Group
Nevro LLC Ticker
Nevro LLC FIGI
All fundamentals and in-depth analysis of Nevro LLC
Our stock analysis for Nevro LLC stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nevro LLC. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.